In ATL, LILRB4.Fc inhibited tumor growth by suppressing the PLC-γ/MAPK/ERK/p70S6K signaling pathway (Figure 3D) and disrupting the homophilic CD166-CD166 intercellular adhesion, thereby interfering with the production and acquisition of growth factors 89. The gene discussed is ALCAM; the disease is neoplasm.